vs
REPLIGEN CORP（RGEN）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ROGERS CORP的季度营收约是REPLIGEN CORP的1.0倍（$200.5M vs $197.9M），REPLIGEN CORP净利率更高（6.7% vs 2.2%，领先4.5%），REPLIGEN CORP同比增速更快（13.6% vs 5.2%），REPLIGEN CORP自由现金流更多（$17.6M vs $1.1M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs -3.3%）
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
RGEN vs ROG — 直观对比
营收规模更大
ROG
是对方的1.0倍
$197.9M
营收增速更快
RGEN
高出8.4%
5.2%
净利率更高
RGEN
高出4.5%
2.2%
自由现金流更多
RGEN
多$16.5M
$1.1M
两年增速更快
RGEN
近两年复合增速
-3.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $197.9M | $200.5M |
| 净利润 | $13.3M | $4.5M |
| 毛利率 | 52.5% | 32.2% |
| 营业利润率 | 9.0% | — |
| 净利率 | 6.7% | 2.2% |
| 营收同比 | 13.6% | 5.2% |
| 净利润同比 | 143.9% | 421.4% |
| 每股收益（稀释后） | $0.24 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RGENROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $197.9M | $201.5M | ||
| Q3 25 | $188.8M | $216.0M | ||
| Q2 25 | $182.4M | $202.8M | ||
| Q1 25 | $169.2M | $190.5M | ||
| Q4 24 | $174.1M | $192.2M | ||
| Q3 24 | $154.9M | $210.3M | ||
| Q2 24 | $154.1M | $214.2M |
净利润RGENROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | $13.3M | $4.6M | ||
| Q3 25 | $14.9M | $8.6M | ||
| Q2 25 | $14.9M | $-73.6M | ||
| Q1 25 | $5.8M | $-1.4M | ||
| Q4 24 | $-30.3M | $-500.0K | ||
| Q3 24 | $-654.0K | $10.7M | ||
| Q2 24 | $3.3M | $8.1M |
毛利率RGENROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 52.5% | 31.5% | ||
| Q3 25 | 53.2% | 33.5% | ||
| Q2 25 | 50.0% | 31.6% | ||
| Q1 25 | 53.6% | 29.9% | ||
| Q4 24 | 26.1% | 32.1% | ||
| Q3 24 | 50.0% | 35.2% | ||
| Q2 24 | 49.8% | 34.1% |
营业利润率RGENROG
| Q1 26 | — | — | ||
| Q4 25 | 9.0% | 3.5% | ||
| Q3 25 | 8.9% | 7.3% | ||
| Q2 25 | 7.6% | -33.3% | ||
| Q1 25 | 3.9% | -0.2% | ||
| Q4 24 | -17.7% | -6.6% | ||
| Q3 24 | -5.1% | 6.9% | ||
| Q2 24 | 1.0% | 5.3% |
净利率RGENROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | 6.7% | 2.3% | ||
| Q3 25 | 7.9% | 4.0% | ||
| Q2 25 | 8.2% | -36.3% | ||
| Q1 25 | 3.4% | -0.7% | ||
| Q4 24 | -17.4% | -0.3% | ||
| Q3 24 | -0.4% | 5.1% | ||
| Q2 24 | 2.2% | 3.8% |
每股收益（稀释后）RGENROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.24 | $0.20 | ||
| Q3 25 | $0.26 | $0.48 | ||
| Q2 25 | $0.26 | $-4.00 | ||
| Q1 25 | $0.10 | $-0.08 | ||
| Q4 24 | $-0.55 | $-0.04 | ||
| Q3 24 | $-0.01 | $0.58 | ||
| Q2 24 | $0.06 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $767.6M | $195.8M |
| 总债务越低越好 | $542.2M | — |
| 股东权益账面价值 | $2.1B | $1.2B |
| 总资产 | $2.9B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.26× | — |
8季度趋势，按日历期对齐
现金及短期投资RGENROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $767.6M | $197.0M | ||
| Q3 25 | $748.7M | $167.8M | ||
| Q2 25 | $708.9M | $157.2M | ||
| Q1 25 | $697.2M | $175.6M | ||
| Q4 24 | $757.4M | $159.8M | ||
| Q3 24 | $784.0M | $146.4M | ||
| Q2 24 | $809.1M | $119.9M |
总债务RGENROG
| Q1 26 | — | — | ||
| Q4 25 | $542.2M | — | ||
| Q3 25 | $537.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $525.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益RGENROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $2.1B | $1.2B | ||
| Q3 25 | $2.1B | $1.2B | ||
| Q2 25 | $2.1B | $1.2B | ||
| Q1 25 | $2.0B | $1.3B | ||
| Q4 24 | $2.0B | $1.3B | ||
| Q3 24 | $2.0B | $1.3B | ||
| Q2 24 | $2.0B | $1.3B |
总资产RGENROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $2.9B | $1.4B | ||
| Q3 25 | $2.9B | $1.4B | ||
| Q2 25 | $2.9B | $1.5B | ||
| Q1 25 | $2.9B | $1.5B | ||
| Q4 24 | $2.8B | $1.5B | ||
| Q3 24 | $2.8B | $1.5B | ||
| Q2 24 | $2.9B | $1.5B |
负债/权益比RGENROG
| Q1 26 | — | — | ||
| Q4 25 | 0.26× | — | ||
| Q3 25 | 0.26× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $25.7M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $17.6M | $1.1M |
| 自由现金流率自由现金流/营收 | 8.9% | 0.5% |
| 资本支出强度资本支出/营收 | 4.1% | 2.3% |
| 现金转化率经营现金流/净利润 | 1.93× | 1.29× |
| 过去12个月自由现金流最近4个季度 | $93.9M | $70.1M |
8季度趋势，按日历期对齐
经营现金流RGENROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $25.7M | $46.9M | ||
| Q3 25 | $48.1M | $28.9M | ||
| Q2 25 | $28.6M | $13.7M | ||
| Q1 25 | $15.0M | $11.7M | ||
| Q4 24 | $39.2M | $33.7M | ||
| Q3 24 | $49.3M | $42.4M | ||
| Q2 24 | $42.2M | $22.9M |
自由现金流RGENROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $17.6M | $42.2M | ||
| Q3 25 | $43.4M | $21.2M | ||
| Q2 25 | $21.5M | $5.6M | ||
| Q1 25 | $11.4M | $2.1M | ||
| Q4 24 | $33.6M | $18.3M | ||
| Q3 24 | $42.3M | $25.2M | ||
| Q2 24 | $37.4M | $8.8M |
自由现金流率RGENROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | 8.9% | 20.9% | ||
| Q3 25 | 23.0% | 9.8% | ||
| Q2 25 | 11.8% | 2.8% | ||
| Q1 25 | 6.8% | 1.1% | ||
| Q4 24 | 19.3% | 9.5% | ||
| Q3 24 | 27.3% | 12.0% | ||
| Q2 24 | 24.3% | 4.1% |
资本支出强度RGENROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 4.1% | 2.3% | ||
| Q3 25 | 2.5% | 3.6% | ||
| Q2 25 | 3.9% | 4.0% | ||
| Q1 25 | 2.1% | 5.0% | ||
| Q4 24 | 3.2% | 8.0% | ||
| Q3 24 | 4.5% | 8.2% | ||
| Q2 24 | 3.1% | 6.6% |
现金转化率RGENROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | 1.93× | 10.20× | ||
| Q3 25 | 3.23× | 3.36× | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 2.57× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | 12.70× | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
